Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Effect of Hydrogen-rich Water During Tapering on Recovery After Functional Overreaching in Basketball Players

15. Juli 2026 aktualisiert von: Jakub Krejci, Palacky University

Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial

The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:

  • Does hydrogen-rich water improve autonomic recovery after functional overreaching?
  • Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?

Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:

  • Complete a training cycle including normal training, functional overreaching, and tapering.
  • Consume hydrogen-rich or placebo water daily during the one-week tapering period.
  • Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.

The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.

Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

  • Tschechien
      • Olomouc, Tschechien, 77111
        • Palacky University, Faculty of Physical Culture
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Competitive male basketball players.
  • Signed informed consent.
  • Completion of entry medical and laboratory screening.

Exclusion Criteria:

  • Acute injury or infection.
  • History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
  • Use of medication affecting recovery markers or study results.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Hydrogen-rich water
Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period.
Nahrungsergänzungsmittel: Hydrogen-rich water
Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm.
Andere Namen:
  • Tirtan generator (Nutristamina, Ostrava, Czech Republic)
Placebo-Komparator: Placebo water
Placebo water administered at a dose of 2.5 L per day during a one-week tapering period.
Nahrungsergänzungsmittel: Placebo water
Tap water without molecular hydrogen.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
RMSSD
Zeitfenster: One-week change between post-overreaching and post-taper.
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
One-week change between post-overreaching and post-taper.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Creatine kinase
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood creatine kinase concentration is used as a marker of muscle damage.
One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein
Zeitfenster: One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein concentration is used as a marker of systemic inflammatory.
One-week change between post-overreaching and post-taper.
Cortisol
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood cortisol concentration is used as a marker of physiological stress response.
One-week change between post-overreaching and post-taper.
Testosterone
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood testosterone concentration is used as a marker related to anabolic-catabolic balance.
One-week change between post-overreaching and post-taper.
Urea
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood urea concentration is used as a marker related to metabolic and protein-turnover stress.
One-week change between post-overreaching and post-taper.
Leukocytes
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood leukocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Lymphocytes
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Neutrophils
Zeitfenster: One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of imflammatory response to training.
One-week change between post-overreaching and post-taper.
Reactive strength index
Zeitfenster: One-week change between post-overreaching and post-taper.
Reactive strength index is used as an marker of neuromuscular function of the lower limbs and is measured using a drop jump.
One-week change between post-overreaching and post-taper.
Hangrip test
Zeitfenster: One-week change between post-overreaching and post-taper.
Handgrip test is used as a marker of forearm muscle strength and is measured using a dynamometer.
One-week change between post-overreaching and post-taper.
20-m sprint
Zeitfenster: One-week change between post-overreaching and post-taper.
20-m sprint test is used to assess linear speed.
One-week change between post-overreaching and post-taper.
Repeated sprint
Zeitfenster: One-week change between post-overreaching and post-taper.
20 x 15 m repeated sprint test is used to asses repeated sprint ability.
One-week change between post-overreaching and post-taper.
Agility T-test
Zeitfenster: One-week change between post-overreaching and post-taper.
Agility T-test is used to assess planned change-of-direction performance.
One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test
Zeitfenster: One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test is used to assess basketball-specific performance.
One-week change between post-overreaching and post-taper.
Muscle soreness
Zeitfenster: One-week change between post-overreaching and post-taper.
Muscle soreness is assessed subjectively using a visual analog scale, which is represented by a 100 mm line marked 0 (no pain) and 100 (worst imaginable pain).
One-week change between post-overreaching and post-taper.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Palacky University

Ermittler

  • Hauptermittler: Jan Kvas, Palacky University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. August 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

15. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. Juli 2026

Zuerst gepostet (Tatsächlich)

20. Juli 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. Juli 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Juli 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • FTK_2026_13

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All IPD that underlie results in a publication.

IPD-Sharing-Zeitrahmen

Beginning 1 month after the publication of results with no end date.

IPD-Sharing-Zugriffskriterien

Anonymized IPD will be uploaded to an open-access data repository.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Gesunde aktive Sportler

Klinische Studien zur Hydrogen-rich water

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Burkina Faso

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren